The global Liver Metastases Treatment Market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.
Colorectal
cancer, breast cancer, and lung cancer are some of the key types that
metastasize to the liver. The incidence of colorectal cancer is expected to
increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the
incidence of breast cancer is expected to increase from 2.26 million in 2020 to
2.74 million in 2030. The rising incidence of these primary indications is
expected to drive space growth.
Majority
of the cancer cases in low and middle-income countries are diagnosed at
advanced stages where the availability of therapeutic options is low. The lack
of availability of early diagnostics methods combined with uncertain
reimbursement scenario for diagnostics are major reasons for delayed diagnosis.
The advanced/metastatic stage of diagnosis provide lucrative growth
opportunities in this space.
On
the other hand, if cancers are diagnosed at advanced stages particularly in
developing nations and LMICS, the treatment rate at such advanced stages is
significantly less, due to unavailability of products and proper reimbursement.
This factor is expected to restrain space growth.
List Of Key Players in the Liver Metastases Treatment
Market
- F.
Hoffmann-La Roche Ltd.
- AstraZeneca
- Eli Lilly
and Company
- Bayer AG
- Ono
Pharmaceutical
- Pfizer, Inc.
- Bristol-Myers
Squibb Company
- Cadila
Pharmaceuticals Ltd.
Related Press
Release@ Liver Metastases Treatment Market Report
Liver Metastases Treatment Market Report Highlights
- By treatment
type, the targeted therapy segment dominated the market with a share of
56.52% to the presence of approved drugs with a price higher than
traditional chemotherapy.
- In 2023,
colorectal cancer dominated the liver metastases treatment market with a
share of 40.55%. Around 25-30% of all colorectal cancers metastasize to
the liver. The availability of various treatment options for CCLM further
contributed to the segments’ dominance.
- Based on
distribution channel, the market was dominated by the hospital pharmacies
segment with a share of 60.07% in 2023. The high rate of hospitalization
for the treatment of liver metastases is one of the major factors for the
dominance of this segment.
- By region,
North America has a high revenue share in the global liver metastases
treatment market in 2023. However, Asia Pacific is expected to be the
fastest growing region during the forecast period.
Liver Metastases Treatment Market
Report Scope
|
Report Attribute |
Details |
|
Market size value in 2024 |
USD 1.74 billion |
|
Revenue forecast in 2030 |
USD 2.66 billion |
|
Growth rate |
CAGR of 7.3% from 2024 to 2030 |
|
Base year for estimation |
2023 |
|
Historical data |
2018 - 2022 |
|
Forecast period |
2024 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/454161/rfc
Liver Metastases Treatment Market Segmentation
Grand
View Research has segmented the global liver metastases treatment market report
based on treatment type, primary cancer, distribution channel, and region:
Liver Metastases Treatment Type Outlook (Revenue, USD
Million, 2018 - 2030)
- Chemotherapy
- Targeted
Therapy
- Immunotherapy
Liver Metastases Treatment Primary Cancer Outlook
(Revenue, USD Million, 2018 - 2030)
- Colorectal
Cancer
- Breast
Cancer
Liver Metastases Treatment Distribution Channel Outlook
(Revenue, USD Million, 2018 - 2030)
- Hospital
Pharmacies
- Specialty
Pharmacies
Liver Metastases Treatment Regional Outlook (Revenue, USD
Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment